These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35671338)

  • 1. Pluripotent Stem Cells in Clinical Setting-New Developments and Overview of Current Status.
    Ilic D; Ogilvie C
    Stem Cells; 2022 Sep; 40(9):791-801. PubMed ID: 35671338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials.
    Guhr A; Kobold S; Seltmann S; Seiler Wulczyn AEM; Kurtz A; Löser P
    Stem Cell Reports; 2018 Aug; 11(2):485-496. PubMed ID: 30033087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy.
    Rehakova D; Souralova T; Koutna I
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances.
    Chhabra A
    Stem Cell Rev Rep; 2017 Dec; 13(6):757-773. PubMed ID: 28918520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.
    Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H
    Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the glycosphingolipids of human-induced pluripotent stem cells and human embryonic stem cells.
    Säljö K; Barone A; Vizlin-Hodzic D; Johansson BR; Breimer ME; Funa K; Teneberg S
    Glycobiology; 2017 Apr; 27(4):291-305. PubMed ID: 27932383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives.
    Säljö K; Barone A; Mölne J; Rydberg L; Teneberg S; Breimer ME
    Sci Rep; 2017 Oct; 7(1):13072. PubMed ID: 29026098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Editing in Human Pluripotent Stem Cells: Recent Advances for Clinical Therapies.
    Şişli HB; Hayal TB; Seçkin S; Şenkal S; Kıratlı B; Şahin F; Doğan A
    Adv Exp Med Biol; 2020; 1237():17-28. PubMed ID: 31728915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X chromosome inactivation in human pluripotent stem cells as a model for human development: back to the drawing board?
    Geens M; Chuva De Sousa Lopes SM
    Hum Reprod Update; 2017 Sep; 23(5):520-532. PubMed ID: 28582519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human embryonic and induced pluripotent stem cells in clinical trials.
    Ilic D; Devito L; Miere C; Codognotto S
    Br Med Bull; 2015; 116():19-27. PubMed ID: 26582538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haematopoietic developmental potential of human pluripotent stem cell lines.
    Tesařová L; Simara P; Stejskal S; Koutná I
    Folia Biol (Praha); 2014; 60 Suppl 1():90-4. PubMed ID: 25369348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges.
    Ford E; Pearlman J; Ruan T; Manion J; Waller M; Neely GG; Caron L
    Cells; 2020 Nov; 9(11):. PubMed ID: 33233861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Manually Curated Database on Clinical Studies Involving Cell Products Derived from Human Pluripotent Stem Cells.
    Kobold S; Guhr A; Mah N; Bultjer N; Seltmann S; Seiler Wulczyn AEM; Stacey G; Jie H; Liu W; Löser P; Kurtz A
    Stem Cell Reports; 2020 Aug; 15(2):546-555. PubMed ID: 32679065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biobanking of human pluripotent stem cells in China.
    Stacey GN; Hao J
    Cell Prolif; 2022 Jul; 55(7):e13180. PubMed ID: 35652319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial and hematopoietic hPSCs differentiation via a hematoendothelial progenitor.
    Vargas-Valderrama A; Ponsen AC; Le Gall M; Clay D; Jacques S; Manoliu T; Rouffiac V; Ser-le-Roux K; Quivoron C; Louache F; Uzan G; Mitjavila-Garcia MT; Oberlin E; Guenou H
    Stem Cell Res Ther; 2022 Jun; 13(1):254. PubMed ID: 35715824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. History and current status of clinical studies using human pluripotent stem cells.
    Kobold S; Bultjer N; Stacey G; Mueller SC; Kurtz A; Mah N
    Stem Cell Reports; 2023 Aug; 18(8):1592-1598. PubMed ID: 37028422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical translation of pluripotent stem cell-based therapies: successes and challenges.
    Christiansen JR; Kirkeby A
    Development; 2024 Apr; 151(7):. PubMed ID: 38564308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The telomerase inhibitor AZT enhances differentiation and prevents overgrowth of human pluripotent stem cell-derived neural progenitors.
    Hu Y; Fang KH; Shen LP; Cao SY; Yuan F; Su Y; Xu M; Pan Y; Chen Y; Liu Y
    J Biol Chem; 2018 Jun; 293(23):8722-8733. PubMed ID: 29628445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes.
    van den Heuvel NH; van Veen TA; Lim B; Jonsson MK
    J Mol Cell Cardiol; 2014 Feb; 67():12-25. PubMed ID: 24370890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
    Zhu H; Kaufman DS
    Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.